5VM
IMPL

5AM Venture Management’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

5AM Venture Management’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,884,791
Closed -$1.24M – 28
2023
Q3 		$1.24M Hold
2,884,791
– – 0.36% 25
2023
Q2 		$3.66M Hold
2,884,791
– – 0.91% 22
2023
Q1 		$4.04M Hold
2,884,791
– – 1.03% 22
2022
Q4 		$10.8M Hold
2,884,791
– – 2.91% 13
2022
Q3 		$14M Hold
2,884,791
– – 2.69% 11
2022
Q2 		$26.9M Hold
2,884,791
– – 6.65% 6
2022
Q1 		$18.4M Hold
2,884,791
– – 4.01% 10
2021
Q4 		$24.9M Hold
2,884,791
– – 4.67% 8
2021
Q3 		$35.1M Hold
2,884,791
– – 7.13% 6
2021
Q2 		$25.5M Buy
+2,884,791
New +$34.4M 6.43% 8

Other funds holding IMPL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

5AM Venture Management's IMPL Position: Q4 2023 in Review

5AM Venture Management sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 2,884,791 shares — an estimated $1.24M sold.

5AM Venture Management first reported a position in IMPL in Q2 2021 and held it in 10 quarters. The position peaked at $35.1M in Q3 2021. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

  • 5AM Venture Management reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • 5AM Venture Management sold 2,884,791 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $1.24M.
  • 5AM Venture Management first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • 5AM Venture Management's Impel Pharmaceuticals Inc. Common Stock position peaked at $35.1M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on 5AM Venture Management's 13F filing for Q4 2023, filed 14 Feb 2024.